<b><i>Background:</i></b> In utero therapeutic approaches for lower urinary tract obstruction (LUTO) have been developed to salvage the fetal kidney function. <b><i>Objective:</i></b> The aim of this work was to report the long-term survival, nephrological, and urological outcome of children treated prenatally for LUTO using operative fetal cystoscopy (FC) and vesicoamniotic shunting (VAS) or both. <b><i>Methods:</i></b> A retrospective study of 48 procedures (23 FC, 25 VAS) was performed on 33 patients (between 2008 and 2018). Reviewed data included prenatal management and clinical follow-up by a pediatric nephrologist and a pediatric urologist. Both intention-to-treat and per-protocol analyses were conducted. <b><i>Results:</i></b> The median follow-up was 3.6 years (0.5–7) for FC and 2.5 years (1.1–5.1) for VAS. There was no difference between FC and VAS in terms of survival (92 vs. 83%, <i>p</i> = 1), complication rate (74 vs. 92%, <i>p</i> = 0.88), or chronic kidney disease (58 vs. 50%, <i>p</i> = 1). The number of procedures was higher in the VAS group: 1.7 (1–3) versus 1.1 (1–2), <i>p</i> = 0.01. With a 30% rate of technical failure, FC added diagnostic value in 3 out of 21 cases. <b><i>Conclusions:</i></b> No difference was found between FC and VAS regarding survival, long-term kidney function, or urological outcome. Despite overly optimistic reports on FC, it lacks reproducibility due to posterior-urethra inadequate visualization and inappropriate instrumentation.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.